Malaria is a deadly disease caused by protozoan parasites of the genus Plasmodium. Effective eradication strategies have been elusive, primarily owing to the complex life cycle of Plasmodium and the emergence of drug-resistant strains of P. falciparum, the most lethal Plasmodium species in humans 1 . The majority of the current antimalarial drugs target the asexual blood stage of Plasmodium, in which they parasitize and replicate within erythrocytes 2 . Even though liverand transmission-stage parasites do not cause malarial symptoms, prophylaxis and transmission-blocking drugs are essential for the proactive prevention of disease epidemics and to protect vulnerable populations 3, 4 . Unfortunately, the current antimalarial drugs do not address all of the requirements for the targeting of pan-life-cycle activity. Several recent reports have described next-generation drug candidates that may achieve some of these important goals 2,5-9 . However, eradication will require multiple innovative ways of targeting the parasite [10] [11] [12] . The antimalarial pipeline will therefore benefit from compounds with diverse mechanisms of action, features that should help circumvent the many resistance mechanisms that render existing drugs ineffective.
Malaria is a deadly disease caused by protozoan parasites of the genus Plasmodium. Effective eradication strategies have been elusive, primarily owing to the complex life cycle of Plasmodium and the emergence of drug-resistant strains of P. falciparum, the most lethal Plasmodium species in humans 1 . The majority of the current antimalarial drugs target the asexual blood stage of Plasmodium, in which they parasitize and replicate within erythrocytes 2 . Even though liverand transmission-stage parasites do not cause malarial symptoms, prophylaxis and transmission-blocking drugs are essential for the proactive prevention of disease epidemics and to protect vulnerable populations 3, 4 . Unfortunately, the current antimalarial drugs do not address all of the requirements for the targeting of pan-life-cycle activity. Several recent reports have described next-generation drug candidates that may achieve some of these important goals 2, [5] [6] [7] [8] [9] . However, eradication will require multiple innovative ways of targeting the parasite [10] [11] [12] . The antimalarial pipeline will therefore benefit from compounds with diverse mechanisms of action, features that should help circumvent the many resistance mechanisms that render existing drugs ineffective.
We identified two key features of a successful strategy for overcoming these challenges. The first of these is the application of modern methods of asymmetric organic synthesis to create unique chemical matter; the second is to test the resulting compounds in a series of phenotype-based screens designed to uncover agents that act on targets essential for several stages of the parasite life cycle (that is, multistage activity). We were encouraged by a small-scale pilot experiment that followed this blueprint and yielded the antimalarial agent ML238 (refs [13] [14] [15] . The experiments described here excluded this earlier pilot set of compounds.
We tested synthetic compounds with structures that were inspired by the structural complexity and diversity of the entire ensemble of natural products, rather than by specific natural products. In this way, we deliberately break the link to natural selection and the limitations it provides in terms of target diversity 16 . A high-throughput P. falciparum phenotypic screen of infected erythrocytes was used to detect inhibitors of parasite growth, with counter-screens using parasites that are resistant to approved or developmental drugs, and with liver-and transmission-stage parasites used to facilitate the discovery of compounds that act through novel mechanisms of action and target multiple stages of malarial infection.
Approximately 100,000 compounds, synthesized at the Broad Institute using the build/couple/pair strategy 17, 18 of diversity-oriented synthesis (DOS), were screened against a multi-drug-resistant strain (P. falciparum strain Dd2) using a phenotypic blood-stage growthinhibition assay, which models a human blood-stage infection. Compounds scored as positives were counter-screened in parallel Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate whether antimalarial agents with novel mechanisms of action could be discovered using a diverse collection of synthetic compounds that have three-dimensional features reminiscent of natural products and are underrepresented in typical screening collections. We report the identification of such compounds with both previously reported and undescribed mechanisms of action, including a series of bicyclic azetidines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase. These molecules are curative in mice at a single, low dose and show activity against all parasite life stages in multiple in vivo efficacy models. Our findings identify bicyclic azetidines with the potential to both cure and prevent transmission of the disease as well as protect at-risk populations with a single oral dose, highlighting the strength of diversity-oriented synthesis in revealing promising therapeutic targets.
against a panel of parasite isolates and diverse drug-resistant clones to deprioritize compounds with previously identified mechanisms of action ( Table 1 and Supplementary Tables 1, 2) were selected. This layered screening process also yielded other series not described here that may merit attention in the future (available at the Malaria Therapeutics Response Portal, http://portals.broadinstitute. org/mtrp/). Underlying features of DOS helped to guide the selection and development of the four nominated series. The compound collection includes stereoisomeric families that yield stereochemistry-based structure-activity relationships (SSAR); their inclusion indicated the possibility of selective interactions with targets. The short, modular pathways, entailing inter-and intramolecular coupling reactions, facilitate medicinal chemistry optimization. Three of the four series yielded new compound scaffolds against known targets. These include: (i) disruptors of sodium ion regulation mediated by P. falciparum ATPase4 (ref. 9; BRD0026 is active against asexual and late sexual blood stages of parasites, Fig. 1b and Extended Data Fig. 1a-d Table 3 ). The fourth series was found to inhibit a previously unknown antimalarial target and is characterized in detail below.
Bicyclic azetidines inhibit cytosolic Pf PheRS
The bicyclic azetidine BRD3444 showed multistage activity in vitro (P. falciparum Dd2, blood stage, half-maximal effective concentration (EC 50 ) = 9 nM; P. falciparum 3D7, transmission stage, gametocyte IV-V, EC 50 = 663 nM; P. berghei strain ANKA, liver stage, EC 50 = 140 nM; Fig. 1e , Extended Data Table 1 and Supplementary  Table 1 ). To elucidate the mechanism of action of the bicyclic azetidine series, three resistant lines were evolved against BRD1095 ( Fig. 2a and Extended Data Fig. 2b ), a derivative of BRD3444 with increased aqueous solubility, from eight independent cultures (> 8 × 10 9 inocula). After more than 3 months of drug pressure, EC 50 values were increased by 4-84-fold. Two clones were obtained from each culture and genomic DNA from each clone was analysed via whole-genome sequencing (Fig. 3a, b and Supplementary Table 4 ). Analysis of resistant clones revealed that each had at least one non-synonymous single-nucleotide variant (SNV) in the PF3D7_0109800 locus, which is predicted to encode the alpha subunit of the cytosolic phenylalanyl-tRNA synthetase (Pf PheRS) showing that stereoisomers at the C 2 position are equipotent, which suggests that this position is not necessary for activity. c, X-ray crystal structure of BRD7929 showing 3D conformation (BRD7929 was crystallized as a salt with two equivalents of l-tartaric acid; only the structure of BRD7929 is shown for clarity).
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of P. falciparum (ref. 22 ). Examination of more than 100 drugresistant P. falciparum clones failed to reveal even a single SNV in the PF3D7_0109800 locus, indicating that the probability of Pf PheRS having three independent mutations by chance is very low. To confirm that cytosolic PheRS is the molecular target of BRD1095, the compound was assayed against purified recombinant proteins. BRD1095 inhibited the aminoacylation activity of recombinant Pf PheRS in a concentration-dependent manner (half-maximal inhibitory concentration (IC 50 ) = 46 nM; Fig. 3c ). We also reasoned that if the primary antiplasmodial mechanism of the bicyclic azetidine series was via inhibition of Pf PheRS activity, then IC 50 values for the aminoacylation activity of purified recombinant Pf PheRS proteins should correlate with EC 50 values obtained in parasite growth inhibition assays. Indeed, a high correlation between the two parameters (r 2 = 0.89) was observed using 16 synthetic analogues of BRD1095 covering a range of activities ( Fig. 3d and Extended Data Table 2 ). This notable correlation, together with the aforementioned genetic evidence, indicates that cytosolic Pf PheRS is the relevant molecular target of the bicyclic azetidine series. In addition, supplementation with exogenous l-phenylalanine (but not d-phenylalanine, l-aspartic acid, l-threonine or l-tyrosine) to the in vitro culture medium increased the EC 50 value of BRD1095 in a concentration-dependent manner (Supplementary Table 5 ).
Owing to its newfound susceptibility to inhibition, Pf PheRS joins the aminoacyl-tRNA synthetase class of emerging targets for antimalarial agents [23] [24] [25] [26] [27] [28] [29] . Although they share common tRNA esterification catalytic activities, these proteins are structurally diverse and physiologically distinct enzymes. The target described here (P. falciparum cytosolic PheRS) is unique as it is the first member of the class in which inhibition, as we will describe, results in elimination of asexual blood-, liver-and transmission-stage parasites, preventing disease transmission, ensuring prophylaxis and providing single-dose cures of the disease in mouse models of malaria.
Optimization of the bicyclic azetidine series
BRD3444 exhibited poor solubility (< 1 μ M in PBS), high intrinsic clearance in human and mouse microsomes (Cl int = 142 and 248 μ l min −1 mg −1 , respectively) and a high volume of distribution (V ss = 12 l kg −1 ; all data found in Extended Data Table 3 ). These results translated to a half-life of 3.7 h in an intravenous pharmacokinetic study in CD-1 mice. Analysis of all eight stereoisomers of BRD3444 included in the primary screen revealed that activity against P. falciparum Dd2 parasites was predominantly found among two isomers differing in stereochemistry at the C 2 position (Fig. 2a, b) . Therefore, we postulated that the C 2 position could be manipulated without loss of in vitro potency and could be used to improve the physicochemical and pharmacokinetic properties of the series. The modular synthetic pathway facilitated the synthesis of advanced analogues that included BRD1095 and BRD7929, in which the hydroxymethyl group at position C 2 is replaced with aminomethyl and dimethylaminomethyl substituents, respectively. These bicyclic azetidines showed improved solubility (25 and 15 μ M in PBS, respectively) and greatly improved intrinsic clearance in mouse microsomes (< 20 and 21 μ l min
, respectively), while retaining in vitro potency. In an intravenous and oral pharmacokinetic study in mice, both BRD1095 and BRD7929 displayed greatly improved blood clearance relative to BRD3444. BRD7929 also displayed good bioavailability (80%), superior to that of BRD1095 (50%), and improved in vitro potency against P. cynomolgi and P. falciparum liver-stage and P. falciparum transmission-stage parasites (Extended Data Table 1 ). BRD7929 showed a high V ss of 24 l kg −1 (Extended Data Table 3 ), which, together with a low blood clearance, translated to a long half-life (32 h), making this compound suitable for single-dose oral treatments. The synthesis pathway enabled the laboratory preparation of 7.5 g of BRD7929 for further testing.
BRD7929 shows in vivo efficacy against all life stages
We evaluated the multistage activity of BRD7929 using mouse malaria models. When BRD7929 activity was evaluated in the blood-stage model with the rodent malaria parasite P. berghei using a luciferase reporter, all infected CD-1 mice treated with a single oral 25 mg kg −1 or 50 mg kg −1 dose became parasite-free and remained so up to the 30-day end-point based on bioluminescent imaging (Extended Data Fig. 3a, b) . To evaluate the therapeutic potential of this series, the in vivo efficacy of BRD7929 against the human malaria parasite P. falciparum was determined. Approximately 48 h after inoculation with the blood-stage P. falciparum 3D7 HLH/BRD (expressing firefly luciferase), non-obese diabetic/severe combined immunodeficiency (NOD/ SCID) Il2rγ −/− mice engrafted with human erythrocytes (huRBC NSG) were treated with a single dose of BRD7929 and monitored for 30 days (Fig. 4a and Extended Data Fig. 3c Figure 3 | The bicyclic azetidine series targets the cytoplasmic Pf PheRS. a, P. falciparum Dd2 clones resistant to BRD1095, a derivative of BRD3444 with increased aqueous solubility, were selected in vitro and non-synonymous SNVs were identified via whole-genome sequencing. All clones from three individual flasks contained non-synonymous SNVs within the PF3D7_0109800 locus, which encodes the alpha subunit of the cytoplasmic PheRS. b, The non-synonymous SNVs identified in clones from flask 1 (red), flask 2 (blue), and flask 3 (green) are shown overlaid on a homology model based on the human cytoplasmic PheRS (PDB accession 3L4G) generated in PyMol. c, BRD1095 was assayed against purified recombinant proteins of wild-type cytosolic Pf PheRS and a mutant containing a SNV (giving a L550V substitution), identified from the resistant strain. IC 50 value of the wild-type PheRS was 0.045 μ M, whereas the IC 50 value for BRD1095 L550V was 1.30 μ M (data are mean ± s.d. for two biological and two technical replicates). d, The bicyclic azetidine series showed a strong correlation between blood-stage growth inhibition and biochemical inhibition of cytosolic Pf PheRS activity. We assayed 15 bicyclic azetidine analogues with varying potency against blood-stage parasites (Dd2 strain) against purified recombinant Pf PheRS. The biochemically derived IC 50 values correlate strongly (r 2 = 0.89) with the EC 50 values determined using the blood-stage growth inhibition assay (see Extended Data Table 2 for structure-activity relationship study and chemical structures).
the 25 mg kg −1 single-dose cure observed in the model with P. berghei is estimated to be 27.5 μ M h based on pharmacokinetic studies with CD-1 mice. Thus, single-dose cures were observed in the P. berghei CD-1 and P. falciparum huRBC NSG mouse models at similar drug exposure levels (AUC = 27.5 and 31.4 μ M h, respectively), suggesting that the efficacy against the two Plasmodium species is comparable.
In a P. berghei liver-stage model, none of the CD-1 mice that were treated with a single dose of 5 or 25 mg kg −1 BRD7929 developed blood-stage parasitaemia within a 30-day period following P. berghei sporozoite inoculation (Extended Data Fig. 4a, b) . Furthermore, mice were treated with a single dose of 10 mg kg −1 BRD7929 at various time points before sporozoite inoculation and during liver-stage infection (Extended Data Fig. 4c ). All mice treated within the 3 days before inoculation and during liver-stage infection were completely free of blood-stage parasites for the duration of the experiment (32 days), indicating that BRD7929 has potent causal prophylaxis activity. Next, 1 day after inoculation with P. falciparum (NF54HT-GFP-luc) 30 sporozoites, FRG knockout (Fah
, heavily immunosuppressed) C57BL/6 mice transplanted with human hepatocytes (huHep FRG knockout) 31 were treated with a single oral dose of BRD7929 (10 mg kg
). Human erythrocytes were intraperitoneally injected daily from 5 to 7 days after inoculation. A gradual increase was detected in parasite liver-stage-associated bioluminescence signals from the lower pectoral and upper abdominal regions of the control (vehicle-treated) mice, whereas no increase in bioluminescence signals was observed from the BRD7929-treated mice ( Fig. 4b and Extended Data Fig. 5a ). For quantitative reverse transcription PCR (qRT-PCR) analysis 32 , blood samples were also collected 7 days after inoculation (the first day of the blood stage) 31 and evaluated for the presence of the blood-stage transcript PF3D7_1120200 (expressing the P. falciparum ubiquitin-conjugating enzyme, UCE) (Extended Data Fig. 5b ). The presence of the blood-stage marker was not detected in samples from the BRD7929-treated mice, indicating that BRD7929 eliminated the liver-stage parasites.
Finally, to examine whether BRD7929 has activity against mature gametocytes and prevents parasite transmission to mosquitoes in vivo, CD-1 mice infected with P. berghei were treated with a single oral dose of BRD7929 2 days before exposure to female Anopheles stephensi mosquitoes. One week later, the midguts of the bloodfed mosquitoes were dissected and the number of oocysts was counted (Extended Data Fig. 6a-c) . No oocysts were detected in midguts dissected from mosquitoes fed on mice treated with 5 or 20 mg kg −1 BRD7929, concentrations below those found to be efficacious against asexual blood-stage parasites. To determine whether BRD7929 showed in vivo efficacy against P. falciparum in humanized mouse models, huRBC NSG mice were infected with blood-stage P. falciparum 3D7 HLH/BRD parasites for 2 weeks to allow the development of mature gametocytes. Subsequently, mice were treated with a single oral dose of BRD7929 (12.5 mg kg −1 , AUC = 31.4 μ M h). Blood samples were collected for 11 days after treatment and analysed for the presence of the late-sexual-stage-specific transcript of Pfs25 (expressing P. falciparum 25 kDa ookinete surface-antigen precursor, PF3D7_1031000) using qRT-PCR 32 ( Fig. 4c and Extended Data Fig. 6d-f ). The transcription of Pfs25 decreased to undetectable levels 7 days after treatment. Previous literature reports of in vitro cellular sensitivity showed that the Pfs25 marker had a detection limit of 0.02-0.05 gametocytes μ l −1 (ref. 33), strongly suggesting that BRD7929 has late-stage gametocidal activity and is capable of preventing the transmission of parasites to the mosquito vector at the same level of exposure as that achieves a single-dose cure in the blood stage.
Safety optimization of the bicyclic azetidine series
While no significant cytotoxicity was observed with BRD3444 and BRD3316, moderate cytotoxicity was observed for bicyclic azetidines BRD7929 (half-maximal cytotoxic concentration (CC 50 ) = 9 μ M) and BRD1095 (CC 50 = 16 μ M) in the HepG2 cell line (Extended Data Fig. 7a ). Both BRD1095 and BRD7929 showed inhibition of I Kr (encoded by KCNH2, also known as hERG) (IC 50 = 5.1 and 2.1 μ M, respectively; Extended Data Table 3 ). Medicinal chemistry efforts have shown that mitigation of ion-channel toxicity is possible while maintaining biological activity; for example, BRD3316 shows no significant inhibition of I Kr at > 10 μ M, indicating that cardiotoxicity is not intrinsically linked to this series. While BRD3444 showed timedependent inhibition of CYP3A4, BRD7929 showed no inhibition of any of the major human cytochrome P450 (CYP) isoforms (Extended Data Fig. 7a ). No phototoxicity was observed with this series in BALB/c 3T3 mouse fibroblasts following exposure to UVA light. BRD7929 and BRD3316 show desirable pharmacokinetic properties, including good oral bioavailability (F = 80 and 63%, respectively). In addition, BRD7929 has a long half-life that enables single-dose treatment. Based on in vitro microsomal stability data, BRD7929 and advanced analogues in this series are likely to have a similar profile in oral dose at 0 h (n = 2 for each group, this study was conducted once). Infections were monitored using the in vivo imaging system (IVIS). Bioluminescent intensity was quantified from each mouse and plotted against time. The dotted horizontal line represents the mean bioluminescence intensity level obtained from all the animals before the parasite inoculation. No recrudescence was observed as low as a single 25 mg kg −1 dose of BRD7929 in the infected animals (see Extended Data  Fig. 3b) . b, huHep FRG-knockout mice were inoculated intravenously with P. falciparum (NF54HT-GFP-luc) sporozoites. BRD7929 was administered as a single 10 mg kg −1 oral dose 1 day after inoculation, and daily engraftment of human erythrocytes was initiated 5 days after inoculation (n = 2 for each group, this study was conducted once).
Infections were monitored using IVIS. The dotted horizontal line represents the mean bioluminescence intensity level obtained from all the animals before the sporozoite inoculation. No increase in bioluminescence intensity level was observed from the mice treated with BRD7929 (see Extended Data Fig. 5a ). c, huRBC NSG mice were infected with bloodstage P. falciparum (3D7 HLH/BRD ) parasites for 2 weeks (allowing the gametocytes to mature fully) and were treated with a single oral dose of BRD7929 (12.5 mg kg −1 ). Blood samples were collected for 11 days and analysed for the presence of the asexual marker SBP1 and the mature gametocyte marker Pfs25 using qRT-PCR (n = 2 for each group, this study was conducted once). The transcription of both SBP1 and Pfs25 decreased to undetectable levels 7 days after treatment, strongly suggesting that BRD7929 eliminates both asexual and gametocyte stages and is capable of preventing parasite transmission to the mosquito (data are mean ± s.d. for three technical replicates for each biological sample).
humans, as metabolic clearance was low for both mouse and human species (Extended Data Table 3 ). BRD7929 was determined to be non-mutagenic using an Ames test in the presence or absence of S9 mix using the Salmonella typhimurium strains TA100, TA1535, TA98, TA1537 and Escherichia coli strain WP2uvrA (Supplementary Table 6 ). Histopathological analysis of mice treated at a high dose (100 mg kg −1 , estimated C max and AUC are 5.4 μ M and 110 μ M h, respectively) showed no adverse findings in the limited number of organs examined (Extended Data Fig. 7b) . Additional studies involving a wider range of organs, doses and compounds will be needed to assess the toxicity of these and related compounds more thoroughly. In NSG mice the estimated C max and AUC of the single-dose cure are 833 nM and 31.4 μ M h, respectively, affording a 6.5-fold safety margin with respect to C max .
Although the emergence of resistance in vitro does not necessarily imply that it will happen in vivo, it is indicative of any mechanisms of resistance that could arise in the future. To examine the propensity of de novo resistance selection, P. falciparum Dd2 cultures with initial inocula ranging from 10 5 to 10 9 parasites were maintained in medium supplemented with 20 nM BRD7929 (the EC 90 of strain Dd2) and monitored for 60 days to identify recrudescent parasitaemia (Extended Data Fig. 7c, d ). No recrudescence was observed in Dd2 cultures exposed to a constant pressure of BRD7929, whereas the minimum inoculum of resistance for atovaquone (EC 90 = 2 nM) was 10 7 , consistent with previous reports 34 .
Discussion
Malaria remains one of the deadliest infectious diseases. Available therapeutic agents are already limited in their efficacy, and drug resistance threatens to diminish our ability to prevent and treat the disease further. Despite a renewed effort to identify compounds with antimalarial activity, the drug discovery and development pipeline lacks target diversity and most malaria drugs are only efficacious during the asexual blood stage of parasite infection.
In these studies, we attempted to identify new antimalarial targets by screening a diverse collection of 100,000 compounds with threedimensional topographic features derived from stereochemical and skeletal elements that are common in natural products but underrepresented in typical screening collections-compounds now accessible using DOS. The compounds are formed in short, modular syntheses that facilitate chemical optimization and manufacturing 35, 36 and have computed physical properties aimed at accelerating drug discovery 37 . We used a primary phenotypic screen to identify a subset of compounds that inhibits parasite growth, counter-screens to prioritize molecules with both novel mechanisms of action and activity at multiple stages of the parasite life cycle, and genetic and biochemical studies to illuminate mechanisms of action. These efforts yielded several series of multiple-stage antimalarial compounds with unique scaffolds that modulate both recently described and established molecular targets.
An earlier pilot study tested key elements of the process above using a distinct 8,000-member DOS library, leading to the discovery of ML238 (refs 13, 14) , a molecule that inhibits parasite growth with nanomolar potency by targeting the reductase domain of P. falciparum cytochrome b (the Q i site), in contrast to the antimalarial agent atovaquone, which targets the oxidase domain of P. falciparum cytochrome b (the Q o site). The study presented here led to many candidate antimalarial agents. We have, thus far, characterized four of these compound series, namely BRD0026 (targeting P. falciparum ATPase4), BRD7539 (targeting P. falciparum DHODH), BRD73842 (targeting P. falciparum PI4K) and BRD3444 (targeting P. falciparum cytoplasmic PheRS). These series were prioritized as they showed in vitro activity against multiple stages of the P. falciparum life cycle, and this was subsequently confirmed in vivo. We anticipate that additional compound series uncovered by these experiments, made available via the Malaria Therapeutics Response Portal (http://portals.broadinstitute.org/mtrp/), will target additional proteins that function as multiple-stage vulnerabilities in Plasmodium and other Apicomplexa pathogens.
Until now, natural products and synthetic drug-like compounds have served as the primary sources of antimalarial drugs. As parasitic susceptibility to traditional chemotypes decreases, it is becoming increasingly necessary to discover lead compounds that are unaffected by existing mechanisms of resistance. DOS coupled with phenotypic screening offers a systematic means to address this need. The results reported here describe a new target and chemotype-Pf PheRS and bicyclic azetidines such as BRD3316 and BRD7929-that have demonstrated the lowest-concentration single-dose cure of three promising next-generation antimalarials in the pipeline 9,38,39 using two mouse models. Single-dose treatments facilitate compliance and overcome cost challenges in resource-deficient regions 40 . The ability of BRD7929 to eliminate blood-stage (both asexual and sexual) and liver-stage parasites suggests bicyclic azetidines have the potential to cure the disease, provide prophylaxis and prevent disease transmission.
Our findings suggest that DOS-derived compound collections, which comprise three-dimensional structures reminiscent of natural products that have yielded many small-molecule probes of diverse mammalian processes 41, 42 , are also a rich resource for identifying targets and readily optimized chemical scaffolds to supplement the current antimalarial pipeline. 
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Designing the next generation of medicines for malaria control and eradication. . Parasites were cultured in medium until parasitaemia reached 3-8%. Parasitaemia was determined by checking at least 500 red blood cells from a Giemsa-stained blood smear. For the compound screening, a parasite dilution at 2.0% parasitaemia and 2.0% haematocrit was created with medium. 25 μ l of medium was dispensed into 384-well black, clear-bottom plates and 100 nl of each compound in DMSO was transferred into assay plates along with the control compound (mefloquine). Next, 25 μ l of the parasite suspension in medium was dispensed into the assay plates giving a final parasitaemia of 1% and a final haematocrit of 1%. The assay plates were incubated for 72 h at 37 °C. 10 μ l of detection reagent consisting of 10× SYBR Green I (Invitrogen; supplied in 10,000× concentration) in lysis buffer (20 mM Tris-HCl, 5 mM EDTA, 0.16% (w/v) Saponin, 1.6% (v/v) Triton X-100) was dispensed into the assay plates. For optimal staining, the assay plates were left at room temperature for 24 h in the dark. The assay plates were read with 505 dichroic mirrors with 485 nm excitation and 530 nm emission settings in an Envision (PerkinElmer). Chemoinformatics clustering. High-throughput screening hits were hierarchically clustered by structural similarity using average linkage on pairwise Jaccard distances 43 between ECFP4 fingerprints 44 . Pipeline Pilot 45 was used for fingerprint and distance calculation; clustering and heat-map generation was done in R (ref. 46 ).
In vitro P. berghei liver-stage assay. HepG2 cells (ATCC) were maintained in DMEM, 10% (v/v) FBS (Sigma), and 1% (v/v) antibiotic-antimycotic in a standard tissue culture incubator (37 °C, 5% CO 2 ). P. berghei (ANKA GFP-luc) infected
A. stephensi mosquitoes were obtained from the New York University Langone Medical Center Insectary. For assays, ∼ 17,500 HepG2 cells per well were added to a 384-well microtitre plate in duplicate. After 18-24 h at 37 °C the media was exchanged and compounds were added. After 1 h, parasites obtained from freshly dissected mosquitoes were added to the plates (4,000 parasites per well), the plates were spun for 10 min at 1,000 r.p.m. and then incubated at 37 °C. The final assay volume was 30 μ l. After a 48-h incubation at 37 °C, Bright-Glo (Promega) was added to the parasite plate to measure relative luminescence. The relative signal intensity of each plate was evaluated with an EnVision (PerkinElmer) system. In vitro P. falciparum liver-stage assay. Micropatterned co-culture (MPCC) is an in vitro co-culture system of primary human hepatocytes organized into colonies and surrounded by supportive stromal cells. Hepatocytes in this format maintain a functional phenotype for up to 4-6 weeks without proliferation, as assessed by major liver-specific functions and gene expression [47] [48] [49] . In brief, 96-well plates were coated homogenously with rat-tail type I collagen (50 μ g ml ) and subjected to soft-lithographic techniques to pattern the collagen into 500-μ m-island microdomains that mediate selective hepatocyte adhesion. To create MPCCs, cryopreserved primary human hepatocytes (BioreclamationIVT) were pelleted by centrifugation at 100g for 6 min at 4 °C, assessed for viability using Trypan blue exclusion (typically 70-90%), and seeded on micropatterned collagen plates (each well contained ∼ 10,000 hepatocytes organized into colonies of 500 μ M) in serum-free DMEM with 1% penicillin-streptomycin. The cells were washed with serum-free DMEM with 1% penicillin-streptomycin 2-3 h later and replaced with human hepatocyte culture medium 48 . 3T3-J2 mouse embryonic fibroblasts were seeded (7,000 cells per well) 24 h after hepatocyte seeding. 3T3-J2 fibroblasts were courtesy of H. Green 50 . MPCCs were infected with 75,000 sporozoites (NF54) (Johns Hopkins University) 1 day after hepatocytes were seeded 48, 49 . After incubation at 37 °C and 5% CO 2 for 3 h, wells were washed once with PBS, and the respective compounds were added. Cultures were dosed daily. Samples were fixed on day 3.5 after infection. For immunofluorescence staining, MPCCs were fixed with − 20 °C methanol for 10 min at 4 °C, washed twice with PBS, blocked with 2% BSA in PBS, and incubated with mouse anti-P. falciparum Hsp70 antibodies (clone 4C9, 2 μ g ml −1 ) for 1 h at room temperature. Samples were washed with PBS then incubated with Alexa 488-conjugated secondary goat anti-mouse for 1 h at room temperature. Samples were washed with PBS, counterstained with the DNA dye Hoechst 33258 (Invitrogen; 1:1,000), and mounted on glass slides with fluoromount G (Southern Biotech). Images were captured on a Nikon Eclipse Ti fluorescence microscope. Diameters of developing liver stage parasites were measured and used to calculate the corresponding area. In vitro P. cynomolgi liver-stage assay. All rhesus macaques (Macaca mulatta) used in this study were bred in captivity for research purposes, and were housed at the Biomedical Primate Research Centre (BPRC; AAALAC-certified institute) facilities under compliance with the Dutch law on animal experiments, European directive 86/609/EEC and with the 'Standard for Humane Care and Use of Laboratory Animals by Foreign Institutions' identification number A5539-01, provided by the Department of Health and Human Services of the US National Institutes of Health. The local independent ethical committee first approved all protocols. Non-randomized rhesus macaques (male or female; 5− 14 years old; one animal per month) were infected with 1 × 10 6 P. cynomolgi (M strain) blood-stage parasites, and bled at peak parasitaemia. Approximately 300 female A. stephensi mosquitoes (Sind-Kasur strain, Nijmegen University Medical Centre St Radboud) were fed with this blood as described previously 51 . Rhesus monkey hepatocytes were isolated from liver lobes as described by previously 52 . Sporozoite infections were performed within 3 days of hepatocyte isolation. Sporozoite inoculation of primary rhesus monkey hepatocytes was performed as described previously 53, 54 . On day 6, intracellular P. cynomolgi malaria parasites were fixed, stained with purified rabbit antiserum reactive against P. cynomolgi Hsp70.1 (ref. 53) , and visualized with FITC-labelled goat anti-rabbit IgG antibodies. Quantification of small 'hypnozoite' exoerythrocytic forms (1 nucleus, a small round shape, a maximal diameter of 7 μ m) or large 'developing parasite' exoerythrocytic forms (more than 1 nucleus, larger than 7 μ m and round or irregular shape) was determined for each well using a high-content imaging system (Operetta, PerkinElmer). In vitro transmission-blocking assay (gametocyte IV-V). P. falciparum 3D7 stage IV-V gametocytes were isolated by discontinuous Percoll gradient centrifugation of parasite cultures treated with 50 mM N-acetyl-d-glucosamine for 3 days to kill asexual parasites. Gametocytes (1.0 × 10 5 ) were seeded in 96-well plates and incubated with compounds for 72 h. In vitro anti-gametocyte activity was measured using CellTiter-Glo (Promega).
In vitro transmission-blocking imaging assay (early, I-III; and late, IV-V, gametocyte).
A detailed description of the method is published elsewhere 55 . In brief, NF54
pfs16-LUC-GFP highly synchronous gametocytes were induced from a single intra-erythrocytic asexual replication cycle. On day 0 of gametocyte development, spontaneously generated gametocytes were removed by VarioMACS magnetic column (MAC) technology. Early stage I gametocytes were collected on day 2 of development and late-stage gametocytes (stage IV) on day 8 using MAC columns. Percentage parasitaemia and haematocrit was adjusted to 10 and 0.1, respectively. 45 μ l of parasite sample were added to PerkinElmer Cell carrier poly-d-lysine imaging plates containing 5 μ l of test compound at 16 doses, including control wells containing 4% DMSO and 50 μ M puromycin (0.4% and 5 μ M final concentrations, respectively), the plates sealed with a membrane (Breatheasy or 4ti-05 15/ST) and incubated for 72 h in standard incubation conditions of 5% CO 2 , 5% O 2 , 90% N 2 and 60% humidity at 37 °C. After incubation, 5 μ l of 0.07 μ g ml −1 MitoTracker Red CM-H2XRos (MTR) (Invitrogen) in PBS was added to each well, and plates were resealed with membranes and incubated overnight under standard conditions. The following day, the plates were brought to room temperature for at least one hour before being measured on the Opera QEHS Instrument. Image analysis was performed using an Acapella (PerkinElmer)-based algorithm that identifies gametocytes of the expected morphological shape with respect to degree of elongation and specifically those parasites that are determined as viable by the MitoTracker Red CM-H2XRos fluorescence size and intensity. IC 50 values were determined using GraphPad Prism 4, using a 4-parameter log dose, nonlinear regression analysis, with sigmoidal dose-response (variable slope) curve fit. P. falciparum standard membrane feeding assay. P. falciparum transmissionblocking activity of BRD7929 was assessed in a standard membrane feeding assay as previously described 56 . In brief, P. falciparum NF54 hsp70-GFP-luc reporter parasites were cultured up to stage V gametocytes (day 14). Test compounds were serially diluted in DMSO and subsequently in RPMI medium to reach a final DMSO concentration of 0.1%. Diluted compound was either pre-incubated with stage V gametocytes for 24 h (indirect mode) or directly added to the blood meal (direct mode). Gametocytes were adjusted to 50% haematocrit, 50% human serum and fed to A. stephensi mosquitoes. All compound dilutions were tested in duplicate in independent feeders. After 8 days, mosquitoes were collected and the relative decrease in oocysts density in the midgut was determined by measurement of luminescence signals in 24 individual mosquitoes from each cage. For each vehicle (control) cage, an additional 10 mosquitoes were dissected and examined by microscopy to determine the baseline oocyst intensity. In vitro resistance selections. In vitro resistance selections were performed as previously described 15 . In brief, approximately 1 × 10 9 P. falciparum Dd2 parasites were treated with 60 nM (EC 99.9 ) or 150 nM (10 × EC 50 ) of BRD1095 in each of four independent flasks for 3-4 days. After the compounds were removed, the cultures were maintained in compound-free complete RPMI growth medium with regular media exchange until healthy parasites reappeared. Once parasitaemia reached 2-4%, compound pressure was repeated and these steps were executed for about 2 months until the initial EC 50 shift was observed. Three out of four independent selections pressured at 60 nM developed a phenotypic EC 50 shift. None of the selections pressured at 150 nM resulted in resistant parasites. After an initial shift in the dose-response phenotype was observed, selection at an increased concentration was repeated in the same manner until at least a threefold shift in EC 50 was observed. Selected parasites were then cloned by limiting dilution.
BRD73842-resistant selections were conducted in a similar manner except that parasites were initially treated at 0.5 μ M (10× EC 50 ) for 4 days or 150 nM (EC 99.9 ) for 2 days in each of two independent flasks. The Y1356N mutant was derived from a flask pressured at 0.5 μ M and the L1418F mutant was developed from one of the flasks exposed to the 150 nM. Whole-genome sequencing and target identification. DNA libraries were prepared for sequencing using the Illumina Nextera XT kit (Illumina), and qualitychecked before sequencing on a Tapestation. Libraries were clustered and run as 100-bp paired-end reads on an Illumina HiSeq 2000 in RapidRun mode, according to the manufacturer's instructions. Samples were analysed by aligning to the P. falciparum 3D7 reference genome (PlasmoDB v. 11.1). To identify SNVs and CNVs, a sequencing pipeline developed for P. falciparum (Plasmodium Type Uncovering Software, Platypus) was used as previously described, with the exception of an increase in the base quality filter from 196.5 to 1,000 (ref. 57). P. falciparum DHODH biochemical assay. Substrate-dependent inhibition of recombinant P. falciparum DHODH protein was assessed in an in vitro assay in 384-well clear plates (Corning 3640) as described previously 58 . A 20-point dilution series of inhibitor concentrations were assayed against 2-10 nM protein with 500 μ M l-dihydroorotate substrate (excess), 18 μ M dodecylubiquinone electron acceptor (∼ K m ), and 100 μ M 2,6-dichloroindophenol indicator dye in assay buffer (100 mM HEPES pH 8.0, 150 mM NaCl, 5% glycerol, 0.5% Triton X-100). Assays were incubated at 25 °C for 20 min and then assessed via OD 600 . Data were normalized to 1% DMSO and excess inhibitor (25 μ M DSM265; ref. 7) . Human DHODH biochemical assay. Substrate-dependent inhibition of recombinant human DHODH protein was assessed in an in vitro assay in 384-well clear plates (Corning 3640) as described previously 59 . A 20-point dilution series of inhibitor concentrations was assayed against 13 nM protein with 1 mM l-dihydroorotate substrate (excess), 100 μ M dodecylubiquinone electron acceptor, and 60 μ M 2,6-dichloroindophenol indicator dye in assay buffer (50 mM Tris HCl pH 8.0, 150 mM KCl, 0.1% Triton X-100). Assays were incubated at 25 °C for 20 min and then assessed via OD 600 . Data were normalized to 1% DMSO and no enzyme. P. vivax PI4K biochemical assay. The synthetic gene for full-length P. vivax PI4K (PVX_098050) was synthesized from GeneArt (ThermoScientific), and was expressed and purified as previously described 20 . Aliquots of P. vivax PI4Kβ were flash-frozen in liquid nitrogen and stored at − 80°C. Full-length human PI4KB (uniprot gene Q9UBF8-2) was expressed and purified as previously described 60 . 100 nM extruded lipid vesicles were made to mimic Golgi organelle vesicles (20% phosphatidylinositol, 10% phosphatidylserine, 45% phosphatidylcholine and 25% phosphatidylethanolamine) in lipid buffer (20 mM HEPES pH 7.5 (room temperature), 100 mM KCl, 0.5 mM EDTA). Lipid kinase assays were carried out using the Transcreener ADP 2 FI Assay (BellBrook Labs) following the published protocol as previously described 61 . 4-μ l reactions ran at 21 °C for 30 min in a buffer containing 30 mM HEPES pH 7.5, 100 mM NaCl, 50 mM KCl, 5 mM MgCl 2 , 0.25 mM EDTA, 0.4% (v/v) Triton X-100, 1 mM TCEP, 0.5 mg ml −1 Golgi-mimic vesicles and 10 μ M ATP. P. vivax PI4Kβ was used at 7.5 nM and human PI4KB was used at 200 nM. Fluorescence intensity was measured using a Spectramax M5 plate reader with excitation at 590 nm and emission at 620 nm (20-nm bandwidth). IC 50 values were calculated from triplicate inhibitor curves using GraphPad Prism software. PheRS homology modelling. The model was built using the SWISS-MODEL online resource [62] [63] [64] and Prime 65 (Schrödinger Release 2015-2: Prime, version 4.0, Schrödinger), with human PheRS (PDB accession 3L4G) as a template for P. falciparum PheRS (PlasmoDB Gene ID: PF3D7_0109800). The template was chosen based on highest sequence identity and similarity identified via PSI-BLAST. Target-template alignment was made using ProMod-II and validated with Prime STA. Coordinates from residues that were conserved between the target and the template were copied from the template to the model, and remaining sites were remodelled using segments from known structures. The side chains were then rebuilt, and the model was finally refined using a force field. P. falciparum cytoplasmic PheRS biochemical assay. Protein sequences of both α -(PF3D7_0109800) and β -(PF3D7_1104000) subunits of cytoplasmic P. falciparum PheRS were obtained from PlasmoDB (http://plasmodb.org/ plasmo/). Full length α -and β -subunit gene sequences optimized for expression in E. coli were cloned into pETM11 (Kanamycin resistance) and pETM20 (ampicillin resistance) expression vectors using Nco1 and Kpn1 sites and co-transformed into E. coli B834 cells. Protein expression was induced by addition of 0.5 mM isopropyl β -d-1-thiogalactopyranoside (IPTG) and cells were grown until an OD 600 of 0.6-0.8 was reached at 37 °C. They were then allowed to grow at 18 °C for 20 h after induction. Cells were separated by centrifugation at 5,000g for 20 min and the bacterial pellets were suspended in a buffer consisting of 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 4 mM β -mercaptoethanol, 15% (v/v) glycerol, 0.1 mg ml −1 lysozyme and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were lysed by sonication and cleared by centrifugation at 20,000g for 1 h. The supernatant was applied on to prepacked NiNTA column (GE Healthcare), and bound proteins were eluted by gradient-mixing with elution buffer (50 mM Tris-HCl (pH 7.5), 80 mM NaCl, 4 mM β -mercaptoethanol, 15% (v/v) glycerol, 1 M imidazole). Pure fractions were pooled and loaded on to heparin column for further purification. Again, bound proteins were eluted using gradient of heparin elution buffer 50 mM Tris-HCl (pH 7.5), 1 M NaCl, 4 mM β-mercaptoethanol, 15% (v/v) glycerol). Pure fractions were again pooled and dialysed overnight into a buffer containing 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 4 mM β-mercaptoethanol, 1 mM DTT and 0.5 mM EDTA. TEV protease (1:50 ratio of protease:protein) was added to the protein sample and incubated at 20 °C for 24 h to remove the polyhistidine tag. Protein was further purified via gel-filtration chromatography on a GE HiLoad 60/600 Superdex column in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 4 mM β-mercaptoethanol, 1 mM MgCl 2 . The eluted protein (a heterodimer of P. falciparum cPheRS) were collected, assessed for purity via SDS-PAGE and stored at − 80 °C.
Nuclear encoded tRNA Phe from P. falciparum was synthesized using an in vitro transcription method as described earlier 22, 66 . Aminoacylation and enzyme inhibition assays for P. falciparum cytosolic PheRS were performed as described earlier 22, 67 . Enzymatic assays were performed in buffer containing 30 mM HEPES (pH 7.5), 150 mM NaCl, 30 mM KCl, 50 mM MgCl 2 , 1 mM DTT, 100 μ M ATP, 100 μ M l-phenylalanine, 15 μ M P. falciparum tRNA Phe , 2 U ml −1 E. coli inorganic pyrophosphatase (NEB) and 500 nM recombinant P. falciparum PheRS at 3 °C. Reactions at different time points were stopped by the addition of 40 mM EDTA and subsequent transfer to ice. Recombinant maltose binding protein was used as negative control. The cPheRS inhibition assays were performed using inhibitor concentrations of 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μ M, 5 μ M and 10 μ M for strong binders and 1 nM, 10 nM, 100 nM, 1 μ M, 10 μ M, 100 μ M and 500 μ M for weaker binders in the assay buffer. Enzymatic and inhibition experiments were performed twice in triplicate. Mammalian cell cytotoxicity assays. Mammalian cells (HepG2, A549, and HEK293) were obtained from the ATCC and cultured routinely in DMEM with 10% FBS and 1% (v/v) antibiotic-antimycotic. For cytotoxicity assays, 1 × 10 6 cells were seeded into 384-well plates 1 day before compound treatment. Cells were treated with ascending doses of compound for 72 h, and viability was measured using Cell-Titer Glo (Promega). All cell lines were tested for Mycoplasma contamination using Universal mycoplasma Detection Kit (ATCC). In vitro ADME/PK and safety assays. In vitro characterization assays (protein binding, microsomal stability, hepatocyte stability, cytochrome P450 (CYP) inhibition, and aqueous solubility) were performed according to industry-standard techniques. Ion channel inhibition studies were performed using the Q-Patch system using standard techniques. Animal welfare. All animal experiments were conducted in compliance with institutional policies and appropriate regulations and were approved by the institutional animal care and use committees for each of the study sites (the Broad Institute, 0016-09-14; Harvard School of Public Health, 03228; Eisai, 13-05, 13-07, 14-C-0027). No method of randomization or blinding was used in this study. In vivo P. berghei blood-stage assay. CD-1 mice (n = 4 per experimental group; female; 6-7-week-old; 20-24 g, Charles River) were intravenously inoculated with approximately 1 × 10 5 P. berghei (ANKA GFP-luc) blood-stage parasites 24 h before treatment and compounds were administered orally (at 0 h). Parasitaemia was monitored by the in vivo imaging system (IVIS SpectrumCT, PerkinElmer) to acquire the bioluminescence signal (150 mg kg −1 of luciferin was intraperitoneally injected approximately 10 min before imaging). In addition, blood smear samples were obtained from each mouse periodically, stained with Giemsa, and viewed under a microscope for visual detection of blood parasitaemia. Animals with parasitaemia exceeding 25% were humanely euthanized. In vivo P. berghei causal prophylaxis assay. CD-1 mice (n = 4 per experimental group; female; 6-7-week-old; 20-24 g, Charles River) were inoculated intravenously with approximately 1 × 10 5 P. berghei (ANKA GFP-luc) sporozoites freshly dissected from A. stephensi mosquitoes. Immediately after infection, the mice were treated with single oral doses of BRD7929; infection was monitored as described for the P. berghei erythrocytic-stage assay. For time-course experiments, the time of compound treatment (single oral dose of 10 mg kg −1 ) was varied from 5 days before infection to 2 days after infection. In vivo P. berghei transmission-stage assay. CD-1 (n = 3 per experimental group; female; 6-7-week-old; 21-24 g, Charles River) mice were infected with P. berghei (ANKA GFP-luc) for 96 h before treatment with vehicle or BRD7929 (day 0).
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On day 2, female A. stephensi mosquitoes were allowed to feed on the mice for 20 min. After 1 week (day 9), the midguts of the mosquitoes were dissected out and oocysts were enumerated microscopically (12.5× magnification). In vivo P. falciparum blood-stage assay. In vivo adapted P. falciparum (3D7 HLH/BRD ) were selected as described previously 68 . In brief, NSG mice (n = 2 per experimental group; female; 4-5-week-old; 19-21 g; The Jackson Laboratory) were intraperitoneally injected with 1 ml of human erythrocytes (O-positive, 50% haematocrit, 50% RPMI 1640 with 5% albumax) daily to generate mice with humanized circulating erythrocytes (huRBC NSG). Approximately 2 × 10 7 bloodstage P. falciparum 3D7 HLH/BRD (ref. 69) were intravenously infected to huRBC NSG mice and > 1% parasitaemia was achieved 5 weeks after infection. After three in vivo passages, the parasites were frozen and used experimentally.
Approximately 48 h after infection with 1 × 10 7 blood-stage of P. falciparum 3D7 HLH/BRD , the mean parasitaemia was approximately 0.4%. huRBC NSG mice were orally treated with a single dose of compound and parasitaemia was monitored for 30 days by IVIS to acquire the bioluminescence signal (150 mg kg −1 of luciferin was intraperitoneally injected approximately 10 min before imaging). In vivo P. falciparum transmission-stage assay. huRBC NSG mice (n = 2 per experimental group; female; 4-5-week-old; 18-20 g; Jackson Laboratory) were infected with blood-stage P. falciparum 3D7 HLH/BRD for 2 weeks to allow the development of mature gametocytes. Subsequently, the mice were treated with a single oral dose of BRD7929. Blood samples were collected for 11 days. For molecular detection of parasite stages, 40 μ l of blood was obtained from control and treated mice. In brief, total RNA was isolated from blood samples using RNeasy Plus Kit with genomic DNA eliminator columns (Qiagen). First-strand cDNA synthesis was performed from extracted RNA using SuperScript III FirstStrand Synthesis System (Life Technologies). Parasite stages were quantified using a stage-specific qRT-PCR assay as described previously 33, 69 . Primers were designed to measure transcript levels of PF3D7_0501300 (ring stage parasites), PF3D7_1477700 (immature gametocytes) and PF3D7_1031000 (mature gametocytes). Primers for PF3D7_1120200 (P. falciparum UCE) transcript were used as a constitutively expressed parasite marker. The assay was performed using cDNA in a total reaction volume of 20 μ l, containing primers for each gene at a final concentration of 250 nM. Amplification was performed on a Viia7 qRT-PCR machine (Life Technologies) using SYBR Green Master Mix (Applied Biosystems) with the following reaction conditions: 1 cycle × 10 min at 95 °C and 40 cycles × 1 s at 95 °C and 20 s at 60 °C. Each cDNA sample was run in triplicate and the mean C t value was used for the analysis. C t values obtained above the cut-off (negative control) for each marker were considered negative for the presence of specific transcripts. Blood samples from each mouse before parasite inoculation were also tested for 'background noise' using the same primer sets. No amplification was detected from any samples. In vivo P. falciparum liver-stage assay. FRG knockout on C57BL/6 (human repopulated, > 70%) mice (huHep FRG knockout; n = 2 per experimental group; female; 5.5-6-month-old; 19-21 g; Yecuris) were inoculated intravenously with approximately 1 × 10 5 P. falciparum (NF54HT-GFP-luc) sporozoites and BRD7929 was administered as a single 10 mg kg −1 oral dose one day after inoculation 31 . Infection was monitored daily by IVIS. Daily engraftment of human erythrocytes (0.4 ml, O-positive, 50% haematocrit, 50% RPMI 1640 with 5% albumax) was initiated 5 days after inoculation. For qPCR analysis, blood samples (40 μ l) were collected 7 days after inoculation. For molecular detection of the bloodstage parasite, 40 μ l of blood was obtained from control and treated mice. In brief, total RNA was isolated from blood samples using RNeasy Plus Kit with genomic DNA eliminator columns (Qiagen). First-strand cDNA synthesis was performed from extracted RNA using SuperScript III First-Strand Synthesis System (Life Technologies). The presence of the blood-stage parasites was quantified using a highly stage-specific qRT-PCR assay as described previously 33, 70 . Primers were designed to measure transcript levels of PF3D7_1120200 (P. falciparum UCE). The assay was performed using cDNA in a 20 μ l total reaction volume containing primers for each gene at a final concentration of 250 nM. Amplification was performed on a Viia7 qRT-PCR machine (Life Technologies) using SYBR Green Master Mix (Applied Biosystems) and the reaction conditions are as follows: 1 cycle × 10 min at 95 °C and 40 cycles × 1 s at 95 °C and 20 s at 60 °C. Each cDNA sample was run in triplicate and the mean C t value was used for the analysis. C t values obtained above the cut-off (negative control) for each marker were considered negative for presence of specific transcripts. Blood samples from each mouse were also tested for background noise using the same primer sets before parasite inoculation. No amplification was detected from any samples. Resistance propensity determination assay. In vitro cultures of P. falciparum Dd2, with the initial inocula ranging from 10 5 to 10 9 parasites, were maintained in complete medium supplemented with 20 nM of BRD7929 (EC 90 against Dd2). Media was replaced with fresh compound added daily and cultures monitored for 60 days to identify propensity for recrudescent parasitaemia as described 34 . Atovaquone was used as a control (EC 90 = 2 nM). Solubility assay. Solubility was determined in PBS pH 7.4 with 1% DMSO. Each compound was prepared in triplicate at 100 μ M in both 100% DMSO and PBS with 1% DMSO. Compounds were allowed to equilibrate at room temperature with a 750 r.p.m. vortex shake for 18 h. After equilibration, samples were analysed by UPLC-MS (Waters) with compounds detected by single-ion reaction detection on a single quadrupole mass spectrometer. The DMSO samples were used to create a two-point calibration curve to which the response in PBS was fit. Plasma protein binding assay. Plasma protein binding was determined by equilibrium dialysis using the Rapid Equilibrium Dialysis (RED) device (Pierce Biotechnology) for both human and mouse plasma. Each compound was prepared in duplicate at 5 μ M in plasma (0.95% acetonitrile, 0.05% DMSO) and added to one side of the membrane (200 μ l) with PBS pH 7.4 added to the other side (350 μ l). Compounds were incubated at 37 °C for 5 h with 350 r.p.m. orbital shaking. After incubation, samples were analysed by UPLC-MS (Waters) with compounds detected by SIR detection on a single quadrupole mass spectrometer. hERG channel inhibition assay. The required potency to inhibit the hERG channel in expressed cell lines were evaluated using an automated patch-clamp system (QPatch-HTX). Mouse pharmacokinetics assay. Pharmacokinetics of BRD3444 and BRD1095 were performed by Shanghai ChemPartner Co. Ltd., following single intravenous and oral administrations to female CD-1 mice. BRD3444 and BRD1095 were formulated in 70% PEG400 and 30% aqueous glucose (5% in H 2 O) for intravenous and oral dosing. Test compounds were dosed as a bolus solution intravenously at 0.6 mg kg −1 (dosing solution; 70% PEG400 and 30% aqueous glucose, 5% in H 2 O) or dosed orally by gavage as a solution at 1 mg kg −1 (dosing solution; 70% PEG400 and 30% aqueous glucose, 5% in H 2 O) to female CD-1 mice (n = 9 per dose route). Pharmacokinetic parameters of BRD7929 and BRD3316 were determined in CD-1 mice. BRD7929 and BRD3316 were formulated in 10% ethanol, 4% Tween, 86% saline for both intravenous and oral dosing. Pharmacokinetic parameters were estimated by non-compartmental model using WinNonlin 6.2. Pharmacokinetic parameters for BRD7929 and BRD3316 were estimated by a non-compartmental model using proprietary Eisai software. Pharmacokinetic parameters of BRD7539 and BRD9185 were determined in CD-1 mice. Compounds were formulated in 70% PEG300 and 30% (5% glucose in H 2 O) at 0.5 mg ml −1 for oral dosing, and 5% DMSO, 10% cremophor, and 85% H 2 O at 0.25 mg ml −1 for intravenous formulation. Pharmacokinetic parameters were estimated by non-compartmental model using WinNonlin 6.2. Pharmacokinetics of BRD7539 and BRD9185 were performed by WuXi AppTec. The protocol was approved by Eisai IACUC, 13-07, 13, 05, and 14-c-0027. Metabolic stability assay. Compounds were evaluated in vitro to determine their metabolic stability in incubations containing liver microsomes or hepatocytes of mouse and human. In the presence of NADPH, liver microsomes (0.2 mg ml −1 ) from mouse (CD-1) and human were incubated with compounds (0.5 and 5 μ M) for 0, 10 and 90 min. The depletion of compounds in the incubation mixtures, determined using liquid chromatography tandem mass spectromety LC-MS/MS, was used to estimate K m and V max values and determine half-lives for both mouse and human microsomes. CYP inhibition assay. Compounds were evaluated in vitro for the potential inhibition of human cytochrome P450 (CYP) isoforms using human liver microsomes. Two concentrations (1 and 10 μ M) of compound were incubated with pooled liver microsomes (0.2 mg ml ) and a cocktail mixture of probe substrates for selective CYP isoform. The selective activities tested were CYP1A2-mediated phenacetin O-demethylation, CYP2C8-mediated rosiglitazone para-hydroxylation, CYP2C9-mediated tolbutamide 4′ -hydroxylation, CYP2C19-mediated (S)-mephenytoin 4′ -hydroxylation, CYP2D6-mediated (± )-bufuralol 1′ -hydroxylation and, CYP3A4/5-mediated midazolam 1′ -hydroxylation. The positive controls tested were α -naphthoflavone for CYP1A2, montelukast for CYP2C8, sulfaphenazole for CYP2C9, tranylcypromine for CYP2C19, quinidine for CYP2D6, and ketoconazole for CYP3A4/5. The samples were analysed by LC-MS/MS. IC 50 values were estimated using nonlinear regression. Time-dependent inactivation assay. The time-dependent inactivation potential of compounds were assessed in human liver microsomes for CYP2C9, CYP2D6, and CYP3A4/5 by determining K I and k inact values when appropriate. Two concentrations (6 and 30 μ M) of compound were incubated in primary reaction mixtures containing phosphate buffer and 0.2 mg ml −1 human liver microsomes for 0, 5, and 30 min in a 37 °C water bath. The reactions were initiated by the addition of NADPH. Phosphate buffer was substituted for NADPH solution for control. At the respective times, 25 μ l of primary incubation was diluted tenfold into pre-incubated secondary incubation mixture containing each CYP-selective probe substrate in order to assess residual activity. The second incubation time was 10 min. The probe substrates used for CYP1A, 2C9, CYP2C19, CYP2D6,
